# A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC

> **NCT03303495** · PHASE3 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 280 (estimated)

## Conditions studied

- Colorectal Neoplasms
- Neoplasm Metastasis
- Intestinal Neoplasms
- Gastrointestinal Neoplasms
- Digestive System Neoplasms

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** CPT-11
- **DRUG:** 5-FU Bolus
- **DRUG:** 5-FU Infusion
- **DRUG:** l-LV (dl-LV)

## Key facts

- **NCT ID:** NCT03303495
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-11-14
- **Primary completion:** 2017-12-31
- **Final completion:** 2018-12-31
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2017-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03303495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03303495, "A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03303495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*